Dynasty Wealth Management LLC Has $4.48 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Dynasty Wealth Management LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 17.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,176 shares of the company's stock after buying an additional 4,100 shares during the quarter. Dynasty Wealth Management LLC's holdings in Zoetis were worth $4,475,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC lifted its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Zoetis by 5.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock valued at $68,354,000 after purchasing an additional 21,470 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Zoetis by 61.0% in the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock valued at $497,000 after purchasing an additional 1,157 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in Zoetis by 12.6% in the 4th quarter. Advisors Asset Management Inc. now owns 19,733 shares of the company's stock valued at $3,215,000 after purchasing an additional 2,213 shares during the last quarter. Finally, Horizon Investments LLC boosted its holdings in Zoetis by 2.9% in the 4th quarter. Horizon Investments LLC now owns 11,157 shares of the company's stock valued at $1,812,000 after purchasing an additional 314 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $1.54 during midday trading on Thursday, hitting $150.00. 3,575,244 shares of the company's stock were exchanged, compared to its average volume of 2,610,616. The firm has a market cap of $66.78 billion, a P/E ratio of 26.93, a PEG ratio of 2.51 and a beta of 0.91. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The stock's 50 day moving average price is $161.24 and its 200-day moving average price is $161.62.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the previous year, the business earned $1.38 EPS. The company's revenue was up 1.4% on a year-over-year basis. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.33%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.18% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZTS. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler increased their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $204.63.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.